hrp0092rfc1.1 | Diabetes and Insulin Session 1 | ESPE2019

Low Prevalence of Maternal Microchimerism in Japanese Children with Type 1 Diabetes

Ushijima Kikumi , Kikuchi Nobuyuki , Kikuchi Toru , Kawamura Tomoyuki , Urakami Tatsuhiko , Amemiya Shin , Ogata Tsutomu , Yokota Ichiro , Sugihara Shigetaka , Fukami Maki

Background: Vertical transfer of maternal cells to the fetus via the placenta leads to maternal microchimerism (MMc) in children. Previous studies from USA have shown that the prevalence and degree of MMc was significantly higher in patients with type 1 diabetes (T1D) than in their unaffected siblings and control individuals. To date, however, the frequency of MMc in non-Caucasian T1D patients remains to be examined.Methods</stro...

hrp0092rfc1.2 | Diabetes and Insulin Session 1 | ESPE2019

Gabra5 Contributes to Sexual Dimorphism in POMC Neural Activity and Glucose Metabolism

Pei Zhou

Objectives: To test whether Gabra5 in POMC neurons regulates energy balance and glucose metabolism in sexually dimorphic fashion.Methods: POMC-Cre mice received stereotaxic injections of AAV-FLEX-scCAS9 and AAV-FLEX-Gabra5-sgRNA-tdTOMATO into ARH to generate pomc-Gabra5 KO mice. Both male and female mice were fed on regular chow diet or HFD. Food intake, body weight and anal temperature were measured every 4 days. Fat/le...

hrp0092rfc1.3 | Diabetes and Insulin Session 1 | ESPE2019

The Association Between IGF-1 levels and Nonalcoholic Fatty Liver Disease (NAFLD) in Adolescents with Type 2 Diabetes

Orozco Morales Jose Antonio , Torres Tamayo Margarita , Suárez Pilar Dies , López Martínez Briceida , Liliana América , Medina Bravo Patricia Guadalupe

Background: Type 2 diabetes (T2D) is an emerging disease in the pediatric population. The mechanisms responsible for the development of nonalcoholic fatty liver disease (NAFLD) and progression to nonalcoholic steatohepatitis (NASH) in these patients are incompletely understood. Low serum insulin-like growth factor-1 (IGF-1) levels are associated with increased histologic severity of NAFLD. Growing evidence suggests that growth hormone (GH) and IGF-1 may have r...

hrp0092rfc1.4 | Diabetes and Insulin Session 1 | ESPE2019

Estimation of Mody Frequency and Prevalent Subtypes in Pediatric Patients by Targeted NGS

Salamanca Luis , Kadaoui Maria Al , Guerrero Julio , Carcavilla Atilano , Itza Nerea , Mora Cristina , Barreda Ana Coral , Dominguez Jesús , Vallespín Elena , Pozo Angela Del , Solis Mario , Aragonés Angel , Hermoso Florinda , Ramirez Joaquín , Teresa Muñoz Maria , Garzón Lucía , Rodriguez Amparo , Escribano Arantxa , Gonzalez Isabel , Campos Angel

Though up to fourteen different MODY subtypes have been so far described, there are no studies in the literature which have determined their actual frequency and prevalence in pediatric patients.Objectives: To identify the underlying molecular basis in a cohort of pediatric patients with a suspected clinical diagnosis of MODY by targeted NGS.Materials/Methods: Cohort of 60 patient fulfilling MODY c...

hrp0092rfc1.5 | Diabetes and Insulin Session 1 | ESPE2019

Decreased Circulating Levels of MOTS-c in Individuals with Newly Diagnosed Type 1 Diabetes Children

Du Caiqi , Zhang Cai , Liang Yan , Wu Wei , Hou Ling , Luo Xiaoping

Background and Aims: A novel bioactive peptide, mitochondrial-derived peptide (MOTS-c), has recently attracted interests as a potential prevention or therapeutic option for obesity and type 2 diabetes mellitus in mice. MOTS-c profiles have not yet been reported in type 1 diabetes (T1DM). We aimed to determine circulating MOTS-c levels in T1DM and explore the association between MOTS-c levels and various metabolic parameters.Metho...

hrp0092rfc1.6 | Diabetes and Insulin Session 1 | ESPE2019

An Oral Trace Element Supplementation has a Potential Beneficial Effect on Glucose Homeostasis in Transfused Patients with β-Thalassemia Major Complicated with Diabetes Mellitus

Mahmoud Asaad Matter Randa , Elbarbary Nancy , Abdel Rahman Ismail Eman , Wagih Darwish Yasser , Shafik Nada Ahmed , Banoub Veronia Philip

Background: β-thalassemia major (β-TM) is the most common genetically determined chronic hemolytic anemia. Studies reported that patients with β-thalassemia are zinc deficient due to increased utilization of zinc by oxidative stress, increased urinary zinc excretion and sequestration in the liver.The development of abnormal glucose tolerance in β-TM is associated with alteration in oxidant-antioxidant status. Zinc plays an essen...

hrp0092rfc2.1 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Burosumab Resulted in Better Clinical Outcomes Than Continuation with Conventional Therapy in Both Younger (1-4 Years-Old) and Older (5-12 Years-Old) Children with X-Linked Hypophosphatemia

Högler Wolfgang , Imel Erik A. , Whyte Michael P. , Munns Craig , Portale Anthony A. , Ward Leanne , Nilsson Ola , Simmons Jill H. , Padidela Raja , Namba Noriyuki , Cheong Hae Il , Mao Meng , Skrinar Alison , San Martin Javier , Glorieux Francis

In children with X-linked hypophosphatemia (XLH), excess circulating fibroblast growth factor 23 (FGF23) causes hypophosphatemia with consequent rickets, skeletal deformities, and impairments in growth and mobility. Compared to continuation with conventional therapy (oral phosphate and active vitamin D [Pi/D]), switching to treatment with burosumab, a fully human monoclonal antibody against FGF23, showed significantly greater improvement in phosphate homeostasis, rickets sever...

hrp0092rfc2.2 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Does the Treatment with Recombinant Human Growth Hormone Improve Final Height in Patients Affected by X-Linked Hypophosphatemia?

André Julia , Zhukouskaya Volha V. , Rothenbuhler Anya , Lambert Anne-Sophie , Salles Jean-Pierre , Mignot Brigitte , Linglart Agnès

Background/Aim: 25 to 40% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, despite optimal conventional treatment (oral phosphate supplementation and active forms of vitamin D) with final height -2 SDS. Recombinant human growth hormone (rhGH) may be an adjuvant treatment of the growth retardation in these patients. Therefore, the main objective of this study was to describe how rhGH treatment improves final heigh...

hrp0092rfc2.3 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Growth Hormone Effects on Metacarpal Bone Geometry and Bone Age in Growth Hormone-Deficient Children

Martin David D , Ranke Michael B , Henrik Thodberg Hans , Binder Gerhard

Purpose: To track the effects of growth hormone on bone geometry and maturation in children with isolated growth hormone deficiency (GHD).Methods: 299 left hand X-rays from 77 short prepubertal children (54 boys and 23 girls) with isolated GHD were analysed for changes in metacarpal thickness, width, length, medullary diameter, the Bone Health Index (BHI) and bone age (BA) from one year preceding until four years after s...

hrp0092rfc2.4 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Bone Mass and Fracture Prevalence in Childhood Brain Cancer Survivors 2, 5 or 7 Years After Off Therapy

Gallizia Annalisa , Mauro Vera , Crocco Marco , Elsa Maria Allegri Anna , Napoli Flavia , Luisa Garrè Maria , Maghnie Mohamad , Di Iorgi Natascia

Background and Aim: Multifaceted risk factors impair bone mass (BM) in childhood brain cancer survivors(CBCS). Aims of the study were to evaluate bone mass and it's determinant and fracture prevalence in CBCS 2(G+2), 5(G+5) or 7(G+7) years after off therapy (OT).Methods: Seventy-three(G+2), 87(G+5) and 66(G+7)CBCS were evaluated at 12,9±4,2, 14,9±4,4 and 16,6±4,4yrs, respectivel...